Navigation Links
New MagnaBloc™ Product Available from Gradient Medical

Gradient Medical recently started offering QuadraBloc™, a new and improved version of AmWay's MagnaBloc.

Memphis, TN (PRWEB) July 2, 2008 -- AmWay's MagnaBloc™, a long-popular form of pain management, is now available in a new, stronger form: QuadraBloc™, offered by Gradient Medical.

"QuadraBloc has already been released in the United States, and will be available worldwide within 60 sixty days," said John Townsend, President of Gradient Medical, LLC. "We will also be releasing several new products within the next few weeks."

Put simply, the QuadraBloc uses magnetic principles to disrupt the transduction of the electrochemical pain signals to the brain. QuadraBloc uses not one but four magnets and a focusing ring placed in a square or diamond pattern. For maximum pain management the QuadraBloc is placed directly over the irritated nerve, where the gradient of the magnetic field has the strongest impact on the nerve's pain signal.

"QuadraBloc is between two and four times stronger than MagnaBloc," Townsend said. "This technology offers an alternative for superior pain relief for people with back pain, sports injuries, and other sources of chronic pain."

The principles that the QuadraBloc is based on were first published in Environmental Science in 1991. In addition, the device's effectiveness is supported by more than a decade of cell research at the Vanderbilt University School of Medicine and at the Center for Pain Research and Neuromagnetics at the University Medical Center in Nashville, Tennessee, as well as numerous other studies performed around the world. To eliminate the experimenters' biases, several of the studies done have been "double blinded," which is where neither the doctor nor the patient know which group the patient is in: the experimental group, which uses the QuadraBloc device, or the control group, which uses a "placebo" or a dummy device.

"The principles used in creating the QuadraBloc have been scientifically researched and well documented," Townsend said. "All of the results to date demonstrate that QuadraBlocs are safe, low in cost and remarkably effective in treating a large variety of aches and pains."

Townsend indicated that the product has not been approved by FDA, has been sold as an OTC product in 40 countries including the US and is not intended to obviate the need to seek professional assistance for health care professionals.

For more information about Gradient Medical and the QuadraBloc™, including laboratory results, videos, and testimonials, please visit

About Gradient Medical, LLC:
The owner of multiple patents for the design and use of QuadraBlocs, Gradient Medical, LLC is a pioneer in the field of using magnets for health. After AmWay's 10-year license of MagnaBloc expired in April of 2008, Gradient Medical launched the QuadraBloc, which offers non surgical and non drug alternatives for the management of pain. For more information about Gradient Medical's products, including the QuadraBloc, please visit


Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. The Quantum Group Adds New Insurance Product for Physicians
2. Release of Kowalski Book on Attaining Healthy Blood Pressure Coincides with Website Launch, New Endurance Products SR L-Arginine and Grape Seed Extract
3. Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
4. Birchwood Laboratories Expands B-SURE™ Incontinence and Personal Care Product Line™; Three New Products Added Including B-SURE Fresh 'n Go™, B-SURE Bottom Balm™ and B-SURE Traveler™
5. Best Practice Database Adds Research on New Product Commercialization
6. StrionAir System A130 Air Purification Product Reduces Fan Energy by More Than 10 Percent
7. NSF International Certifies Purity of Four Mannatech Products
8. HighPoint Solutions Develops Novel Incentive Compensation Plan for New Benign Prostatic Hyperplasia (BPH) Product
9. Bioniche Secures Final Financing to Scale-up E. coli O157:H7 Vaccine Production
10. Function Drinks Launches New Product to Support Sexual Health
11. Blue Cross and Blue Shield of Georgia Introduces New Individual Products
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, ... country to celebrate their sobriety and show through pictures what a positive difference ... photos this Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy Products, ... heating products business. Cozy Products explains what this means for business moving forward. , ... the Cozy Products business model: to sell personal heaters that reduce energy consumption, are ...
(Date:11/25/2015)... Livonia, MI (PRWEB) , ... November 25, 2015 , ... ... at Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the ... the medical and surgical intensive care units (totaling 30 beds) from May 2014 through ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... found that regular bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. ... , She developed the patent-pending RECOVERY BRA for added comfort and support. The ...
(Date:11/25/2015)... ... , ... Since its launch in 2012, the Regenestem brand ... therapies to patients with chronic degenerative medical conditions. Now, the U.S. Patent and ... , Organizations are required to hold a registered trademark in order to make ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 24, 2015  Thanks to a donor with a ... Medical Center,s Sister Diane Grassilli Center for Women,s Health ... San Francisco . ... forward with a gift of $617,320 that allowed the ... with Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) ...
(Date:11/24/2015)... , Nov. 24, 2015  Array BioPharma Inc. ... Chief Executive Officer, Ron Squarer , will ... in New York.  The public is welcome to ... the Array BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  ... December 2, 2015Time:1:30 p.m. Eastern Time Webcast: ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" ... announced today that the first patient has been enrolled ... a treatment for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States ... Phase 1/2 clinical trial, ESSA intends to demonstrate the ...
Breaking Medicine Technology: